Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeuroRegen Scaffold with BMMCs in Chronic SCI
NCT02688062Phase 2Unknown
- Sponsor
- Chinese Academy of Sciences
- Start
- Jan 2016
- Primary completion
- Dec 2021
- Modality
- Device-based Delivery, Recombinant Proteins and Enzymes, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of NeuroRegen Scaffold and bone marrow mononuclear cells in spinal cord injury (SCI) (2 arms), sponsored by Chinese Academy of Sciences. Primary endpoints: Improvements in ASIA Impairment Scale at 24 months, Improvements in Somatosensory Evoked Potentials at 24 months and 1 more. Status: unknown.
02
Drugs
NeuroRegen Scaffoldbone marrow mononuclear cells
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02688062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02688062.